What is meningococcal B vaccine?

The meningococcal B vaccine (MenB) protects against a fifth type of meningococcal bacterium (called type B). It is fairly new and not yet recommended as a routine vaccination for healthy people. But some kids and teens who are at increased risk for meningococcal disease should get it starting from age 10.

What is the meningococcal B vaccine recommended for?

CDC recommends routine MenB vaccination for: People 10 years or older at increased risk for meningococcal disease.

How many meningococcal B vaccines are required?

Adolescents who receive their first dose of MenACWY vaccine at or after age 16 years do not need a booster dose. Adolescents who are at increased risk due to medical conditions need a 2-dose primary series of MenACWY vaccine administered 8 weeks apart, as well as regular booster doses every 5 years.

What causes meningitis B?

Although it is uncommon, meningitis B (MenB) is a serious infection. It is caused by the bacterium Neisseria meningitidis group B, which can cause an infection of the membrane that surrounds the brain and spinal cord. It can also cause septicemia, a serious infection of the bloodstream.

Who needs meningococcal B vaccine?

Meningococcal B vaccines are recommended for people 10 years or older who are at increased risk for serogroup B meningococcal disease, including: People at risk because of a serogroup B meningococcal disease outbreak. Anyone whose spleen is damaged or has been removed, including people with sickle cell disease.

When did meningitis B vaccine start?

The MenB vaccine was introduced into the UK schedule on 1st September 2015. The UK is the first country in the world to introduce a MenB vaccine into its routine vaccination schedule.

Is meningococcal B vaccine safe?

Available data suggest that MenB vaccines are safe. More than half of the people who get a MenB vaccine have mild problems following vaccination: Soreness, redness, or swelling where the shot was given. Feeling tired (fatigue)

Which vaccine is better Covaxin or Covishield?

‍ With the spread of the Delta variant and the anticipated third wave, studies show a decline in the vaccine’s effectiveness against it. Covishield has fallen to 65% and to 61% for Covaxin. Vaccines do not prevent a person from being infected, they help fight Covid19 infection.